AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3091801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil 30 mg/kg once daily
Number of subjects: 196
Study 3091801 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V 250 mg three times daily
Number of subjects: 196
Study 31307747 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (15 μg/kg)
Number of subjects: 235
Study 31307747 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1.5 μg/kg)
Number of subjects: 235
Study 31307747 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (1.5 μg/kg)
Number of subjects: 235
Study 31307747 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 235
Study 29058822 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg every 4 weeks for 28 weeks
Number of subjects: 91
Study 29058822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 26132774 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-segmentation refinement
Number of subjects: 180
Study 26132774 — intervention group
Group type: COMPARATOR
Intervention: Advanced glaucoma group
Number of subjects: 180
Study 26132774 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal blood vessels proportion
Number of subjects: 180
Study 24819707 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose plus lifestyle advice
Number of subjects: 0
Study 24819707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22203120 — intervention group
Group type: EXPERIMENTAL
Intervention: IT injection without any previous anesthesia
Number of subjects: 69
Study 22203120 — intervention group
Group type: COMPARATOR
Intervention: IT injection with EMLA cream
Number of subjects: 69
Study 22203120 — intervention group
Group type: COMPARATOR
Intervention: IT injection with subcutaneous lidocaine 1%
Number of subjects: 69
Study 22203120 — intervention group
Group type: EXPERIMENTAL
Intervention: IT injection with methylprednisolone
Number of subjects: 69
Study 22203120 — intervention group
Group type: COMPARATOR
Intervention: IT injection with gentamicin
Number of subjects: 69
Study 21029874 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation of ST-segment elevation ≥0.05 mV in V(1) to V(3) leads during early recovery (1 to 4 min)
Number of subjects: 93
Study 21029874 — intervention group
Group type: COMPARATOR
Intervention: No augmentation of ST-segment elevation
Number of subjects: 93
Study 21029874 — intervention group
Group type: EXPERIMENTAL
Intervention: History of syncope alone
Number of subjects: 93
Study 21029874 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic patients
Number of subjects: 93
Study 18569478 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative urodynamics (UDS)
Number of subjects: 72
Study 16011701 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted tests based on O'Brien's method
Number of subjects: 0
Study 16011701 — intervention group
Group type: COMPARATOR
Intervention: O'Brien's test
Number of subjects: 0
Study 12173947 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose creatine supplementation
Number of subjects: 0
Study 12173947 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose creatine supplementation
Number of subjects: 0
Study 12173947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11093435 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular gold sodium thiomalate (GSTM)
Number of subjects: 109
Study 11093435 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular methotrexate (MTX)
Number of subjects: 109
Study 11093435 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositive patients
Number of subjects: 109
Study 11093435 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with double dose of RA linked alleles
Number of subjects: 109
Study 11093435 — intervention group
Group type: EXPERIMENTAL
Intervention: Seronegative patients
Number of subjects: 109
Study 9098861 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (30 microU/mL)
Number of subjects: 21
Study 9098861 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline
Number of subjects: 21
Study 9098861 — intervention group
Group type: EXPERIMENTAL
Intervention: Forskolin
Number of subjects: 21
Study 9098861 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 21
Study 9098861 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin receptor mRNA expression
Number of subjects: 21
Study 8416070 — intervention group
Group type: EXPERIMENTAL
Intervention: Attended stimuli (frequency change)
Number of subjects: 0
Study 8416070 — intervention group
Group type: COMPARATOR
Intervention: Ignored stimuli (intensity deviation)
Number of subjects: 0
Study 3544820 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol
Number of subjects: 7
Study 3544820 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 7
Study 31727694 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 1010
Study 31727694 — intervention group
Group type: COMPARATOR
Intervention: Dalteparin
Number of subjects: 1010
Study 31296180 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic amoxycillin-clavulanic acid
Number of subjects: 718
Study 31296180 — intervention group
Group type: COMPARATOR
Intervention: Expectant management with medical advice
Number of subjects: 718
Study 28251605 — intervention group
Group type: EXPERIMENTAL
Intervention: Totaltrack
Number of subjects: 55
Study 28251605 — intervention group
Group type: COMPARATOR
Intervention: Fastrach
Number of subjects: 55
Study 25966916 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD‐TDV and MMR coadministration
Number of subjects: 210
Study 25966916 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD‐TDV
Number of subjects: 210
Study 25966916 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR
Number of subjects: 210
Study 25966916 — intervention group
Group type: COMPARATOR
Intervention: Active control vaccines
Number of subjects: 210
Study 23768214 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 16
Study 23768214 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 16
Study 21636633 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure with evidence based risk information and two optional interactive internet modules on risk and diagnostic tests
Number of subjects: 1577
Study 21636633 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure with evidence based risk information
Number of subjects: 1577
Study 21636633 — intervention group
Group type: COMPARATOR
Intervention: Official information leaflet of the German colorectal cancer screening programme (control)
Number of subjects: 1577
Study 19349552 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sorafenib 400 mg twice daily on days 2 to 19 plus intravenous paclitaxel 225 mg/m2 and intravenous carboplatin AUC 6 on day 1
Number of subjects: 270
Study 19349552 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus intravenous paclitaxel 225 mg/m2 and intravenous carboplatin AUC 6 on day 1
Number of subjects: 270
Study 16737373 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal confrontations (varied in hostility)
Number of subjects: 0
Study 16737373 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal confrontations (expressed by either a Black or White person)
Number of subjects: 0
Study 16737373 — intervention group
Group type: EXPERIMENTAL
Intervention: Hostile confrontations
Number of subjects: 0
Study 15201249 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous Coronary Intervention (PCI)
Number of subjects: 988
Study 15201249 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Artery Bypass Grafting (CABG)
Number of subjects: 988
Study 15201249 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 988
Study 15201249 — intervention group
Group type: COMPARATOR
Intervention: PCI
Number of subjects: 988
Study 11142539 — intervention group
Group type: EXPERIMENTAL
Intervention: MBTV (MBT plus voucher‐based incentives)
Number of subjects: 60
Study 11142539 — intervention group
Group type: COMPARATOR
Intervention: MBT (M plus behavioral coping skills therapy)
Number of subjects: 60
Study 11142539 — intervention group
Group type: COMPARATOR
Intervention: M (motivational enhancement)
Number of subjects: 60
Study 9272298 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost infusion for five consecutive days (7-hour infusion)
Number of subjects: 8
Study 9272298 — intervention group
Group type: COMPARATOR
Intervention: Iloprost infusion for one day
Number of subjects: 8
Study 7525359 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral danazol, 50 mg/d for 9 months (group I, n = 21)
Number of subjects: 42
Study 7525359 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide depot for 3 months followed by oral danazol, 50 mg/d for 6 months (group II, n = 21)
Number of subjects: 42
Study 3664913 — intervention group
Group type: EXPERIMENTAL
Intervention: Portex epidural catheter
Number of subjects: 150
Study 3664913 — intervention group
Group type: COMPARATOR
Intervention: Vas‐Cath catheter
Number of subjects: 150
Study 31971061 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish-DA
Number of subjects: 368
Study 31971061 — intervention group
Group type: COMPARATOR
Intervention: English-DA
Number of subjects: 368
Study 28627230 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacoinvasive strategy
Number of subjects: 1866
Study 28627230 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention
Number of subjects: 1866
Study 28627230 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled angiography
Number of subjects: 1866
Study 28627230 — intervention group
Group type: COMPARATOR
Intervention: Pharmacoinvasive strategy requiring rescue
Number of subjects: 1866
Study 28431557 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based paste containing vitamin B12
Number of subjects: 600
Study 28431557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 26813135 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 30
Study 26813135 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 30
Study 26813135 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 30
Study 24278915 — intervention group
Group type: EXPERIMENTAL
Intervention: O3 + saline
Number of subjects: 20
Study 24278915 — intervention group
Group type: EXPERIMENTAL
Intervention: O3 + H2O2
Number of subjects: 20
Study 24278915 — intervention group
Group type: COMPARATOR
Intervention: O2 + saline
Number of subjects: 20
Study 21986980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol 15 mg/kg
Number of subjects: 90
Study 21986980 — intervention group
Group type: COMPARATOR
Intervention: Intravenous physiological saline (control group)
Number of subjects: 90
Study 18728172 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy at 33 microg/kg.d
Number of subjects: 177
Study 18728172 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy at 67 microg/kg.d
Number of subjects: 177
Study 18728172 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 177
Study 18728172 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 177
Study 17146980 — intervention group
Group type: EXPERIMENTAL
Intervention: New method for active-comparator trials based on location-scale family of distributions
Number of subjects: 0
Study 17146980 — intervention group
Group type: COMPARATOR
Intervention: Existing methods for sample size estimation
Number of subjects: 0
Study 14631268 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hormone therapy with rivastigmine (n=59)
Number of subjects: 117
Study 14631268 — intervention group
Group type: COMPARATOR
Intervention: Placebo with rivastigmine (n=58)
Number of subjects: 117
Study 11083612 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade nailing
Number of subjects: 100
Study 11083612 — intervention group
Group type: COMPARATOR
Intervention: Retrograde nailing
Number of subjects: 100
Study 9428588 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodopovidone (14 patients)
Number of subjects: 22
Study 9428588 — intervention group
Group type: COMPARATOR
Intervention: Bleomycin (8 patients)
Number of subjects: 22
Study 8087522 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (doxorubicin, etoposide, cyclophosphamide, plus methotrexate or cisplatin) and thoracic radiotherapy (total dose of 45, 55, 65 and 61 Gy)
Number of subjects: 202
Study 8087522 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and thoracic radiotherapy
Number of subjects: 202
Study 2669155 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25 mg/day
Number of subjects: 19
Study 2669155 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 50 mg/day
Number of subjects: 19
Study 2669155 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25 mg plus triamterene (50 mg)
Number of subjects: 19
Study 2669155 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during the three-week single-blind period)
Number of subjects: 19
Study 782970 — intervention group
Group type: EXPERIMENTAL
Intervention: Nose drops
Number of subjects: 193
Study 782970 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray device 1
Number of subjects: 193
Study 782970 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray device 2
Number of subjects: 193
Study 782970 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray device 3
Number of subjects: 193
Study 782970 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesics (for volunteers with fourfold or greater antibody response)
Number of subjects: 193
Study 782970 — intervention group
Group type: COMPARATOR
Intervention: No analgesics (for volunteers with no serological response)
Number of subjects: 193
Study 29730641 — intervention group
Group type: EXPERIMENTAL
Intervention: Aciclovir
Number of subjects: 3
Study 29730641 — intervention group
Group type: COMPARATOR
Intervention: VZIG
Number of subjects: 3
Study 28151459 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/day Nigella sativa (NS-1)
Number of subjects: 74
Study 28151459 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/day Nigella sativa (NS-2)
Number of subjects: 74
Study 28151459 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 74
Study 25734911 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Resistance Training (CRT)
Number of subjects: 18
Study 25734911 — intervention group
Group type: COMPARATOR
Intervention: Periodic Resistance Training (PRT)
Number of subjects: 18
Study 25734911 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CRT and PRT)
Number of subjects: 18
Study 22897742 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic mallet group (MMG)
Number of subjects: 50
Study 22897742 — intervention group
Group type: COMPARATOR
Intervention: Hand mallet group (HMG)
Number of subjects: 50
Study 22897742 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 21851195 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (50 mg)
Number of subjects: 20
Study 21851195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19631846 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulpectomy procedures
Number of subjects: 0
Study 17244178 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive group cognitive treatment (IGCT)
Number of subjects: 100
Study 17244178 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive therapy (ICT)
Number of subjects: 100
Study 17244178 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 100
Study 15908654 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education and counseling
Number of subjects: 142
Study 15908654 — intervention group
Group type: COMPARATOR
Intervention: Individual education and counseling
Number of subjects: 142
Study 12518490 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest SpinBrush Pro (experimental powered toothbrush)
Number of subjects: 140
Study 12518490 — intervention group
Group type: COMPARATOR
Intervention: Oral-B CrossAction (advanced-design manual toothbrush)
Number of subjects: 140
Study 12518490 — intervention group
Group type: COMPARATOR
Intervention: Oral-B 40 Indicator (flat-trimmed toothbrush)
Number of subjects: 140
Study 9807345 — intervention group
Group type: EXPERIMENTAL
Intervention: Peplau's process of practice-based theory development
Number of subjects: 0
Study 8604868 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine/.25% bupivacaine
Number of subjects: 19
Study 8604868 — intervention group
Group type: COMPARATOR
Intervention: .25% bupivacaine alone
Number of subjects: 19
Study 1958449 — intervention group
Group type: EXPERIMENTAL
Intervention: RG 12525 800 mg
Number of subjects: 8
Study 1958449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 7217707 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulation studies
Number of subjects: 32
Study 31478963 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Alcohol Screening Test
Number of subjects: 764
Study 31478963 — intervention group
Group type: EXPERIMENTAL
Intervention: Glasgow Modified Alcohol Withdrawal Scale score
Number of subjects: 764
Study 31478963 — intervention group
Group type: EXPERIMENTAL
Intervention: AWS admission
Number of subjects: 764
Study 31478963 — intervention group
Group type: EXPERIMENTAL
Intervention: Hours since the last drink
Number of subjects: 764
Study 31478963 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 764
Study 31478963 — intervention group
Group type: COMPARATOR
Intervention: Comorbidity
Number of subjects: 764
Study 28464041 — intervention group
Group type: EXPERIMENTAL
Intervention: PopART intervention (universal testing and treatment)
Number of subjects: 121130
Study 24639003 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral EPI navigator
Number of subjects: 8
Study 24639003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartesian EPI navigator
Number of subjects: 8
Study 24639003 — intervention group
Group type: COMPARATOR
Intervention: Radial navigator
Number of subjects: 8
Study 23195630 — intervention group
Group type: EXPERIMENTAL
Intervention: Overload group (OR) during 3 weeks of training
Number of subjects: 24
Study 23195630 — intervention group
Group type: COMPARATOR
Intervention: Normo-trained group (NT) during 3 weeks of training
Number of subjects: 24
Study 23195630 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal incremental test parameters
Number of subjects: 24
Study 23195630 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate and blood lactate concentration changes
Number of subjects: 24
Study 23195630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive performance
Number of subjects: 24
Study 20924024 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 69)
Number of subjects: 139
Study 20924024 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 70)
Number of subjects: 139
Study 19468036 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 40
Study 19468036 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline
Number of subjects: 40
Study 17361851 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including deltamethrin-impregnated bednets, repellent (20% diethyltoluamide and 0.5% permethrin), modification of sand fly resting sites, and health education.
Number of subjects: 20
Study 17361851 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 20
Study 17361851 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention.
Number of subjects: 20
Study 15332389 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 12
Study 15332389 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 40 mg
Number of subjects: 12
Study 15332389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10943876 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral methotrexate (MTX) 15 mg/m2 (increased to 20 mg/m2 after 2 months)
Number of subjects: 88
Study 10943876 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose oral methotrexate (MTX)
Number of subjects: 88
Study 10943876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 1736617 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide (1 of 2 dose levels)
Number of subjects: 18
Study 1736617 — intervention group
Group type: EXPERIMENTAL
Intervention: Dofetilide (high-dose level)
Number of subjects: 18
Study 1736617 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6500758 — intervention group
Group type: EXPERIMENTAL
Intervention: Brand A of furosemide
Number of subjects: 16
Study 6500758 — intervention group
Group type: COMPARATOR
Intervention: Brand B of furosemide
Number of subjects: 16
Study 31564933 — intervention group
Group type: EXPERIMENTAL
Intervention: PEDYPHAR ointment
Number of subjects: 119
Study 31564933 — intervention group
Group type: COMPARATOR
Intervention: Panthenol ointment (control)
Number of subjects: 119
Study 30594223 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive Scheme with motivational interviewing; gift vouchers of US$5.6 for VL < 20 copies/mL at 12 weeks, US$2.8 for VL suppression for the next 3 months, US$5.6 for VL < 20 copies/mL at 1 year.
Number of subjects: 12
Study 30594223 — intervention group
Group type: COMPARATOR
Intervention: Routine HIV care (usual care)
Number of subjects: 12
Study 27623720 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% phenol in almond oil
Number of subjects: 80
Study 27623720 — intervention group
Group type: COMPARATOR
Intervention: 50% dextrose water
Number of subjects: 80
Study 25027180 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐ADP‐agg ≥ 50%
Number of subjects: 184
Study 25027180 — intervention group
Group type: EXPERIMENTAL
Intervention: ACS-setting
Number of subjects: 184
Study 25027180 — intervention group
Group type: EXPERIMENTAL
Intervention: Severely reduced LV function
Number of subjects: 184
Study 22122605 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergame training (24 sessions of 1 hour each)
Number of subjects: 0